Home > Healthcare & Medical Devices > Joint Pain Injections Market

Joint Pain Injections Market Size By Injection (Hyaluronic Acid Injections, Corticosteroid Injections, Platelet Rich Plasma Injections), By Joint (Knee, Shoulder & Elbow, Ankle & Hip), By End-use (Hospitals, Clinics), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2023 – 2032

  • Report ID: GMI5403
  • Published Date: Nov 2022
  • Report Format: PDF

Industry Overview

Joint Pain Injections Market size recorded a valuation of over USD 3.5 billion in 2022 and is poised to depict more than 8.5% CAGR from 2023 to 2032. The surging incidences of musculoskeletal conditions and orthopedic disorders, such as osteoporosis, arthritis, back pain, trauma, etc., are expected to inflate the demand for joint pain injections over the forecast period.

Joint Pain Injections Market

Get more details on this report - Request Free Sample PDF

According to the Global RA Network, an estimated 350 million people across the globe had arthritis in 2021. The number is further estimated to witness a noticeable surge owing to the consistent rise in the geriatric population and the increasing life expectancy. Joint disorders significantly impact the patient's quality of life, productivity, and activity. This has resulted in an increased requirement to introduce efficient management and treatment of these diseases and a rapid shift in epidemiological patterns. In addition, the rising number of surgical interventions for pain relief and management will boost the joint pain injections industry growth through 2032.

Potential risks and complications to act as a restraining factor

Joint pain injections associate several side effects ranging from intense pain and swelling to joint infection, cartilage damage, and nerve damage, which may impede their adoption rate over the coming years. Studies suggest that corticosteroid injections can lead to severe complications, such as skin discoloration, infections, and allergic reactions that may cause adverse health impacts. Besides, these injections are significantly expensive and thus have gained limited acceptance among ailing patients, further impacting market revenues.

Efficient pain management to bolster the adoption of hyaluronic acid injections

Global joint pain injections market by injection

Get more details on this report - Request Free Sample PDF

With regard to injection, joint pain injections market from hyaluronic acid injections segment was valued at over USD 2.4 billion in 2022 and is expected to amass an appreciable market share by 2032. Hyaluronic acid injections are the preferred treatment choice for patients with osteoarthritis who do not respond to conventional treatments. These provide prolonged pain relief for up to 6 months against osteoarthritis knee pain and can be easily administered in clinical or hospital settings. The consistent efforts by leading market players to leverage cutting-edge technologies and viscosupplementation to increase the efficacy of these injections will propel segment share.

Increasing prevalence of orthopedic knee disorders to boost the demand for knee joint pain injections

Based on joint, joint pain injections market from knee segment is projected to garner revenues worth over USD 7 billion by 2032. The segment growth can be credited to the consistent expansion of the elderly population and the subsequent rise in orthopedic knee disorders. According to the National Centers for Biotechnology Information (NCBI), nearly 100,000 to 200,000 cases of anterior cruciate ligament (ACL) sprains and tears were reported in the U.S. in 2021. The surging incidences of knee injuries and pain management procedures will positively influence the industry statistics.

Improved patient outcomes to help hospitals emerge as a major end-user segment

Global joint pain injections market by end-use

Get more details on this report - Request Free Sample PDF

Regarding the end-user, joint pain injections market from hospital segment is anticipated to reach over USD 5.4 billion by 2032. Hospital settings ensure the availability of skilled orthopedic physicians and advanced surgical equipment resulting in better patient outcomes. A remarkable growth in the number of patients undergoing joint pain management and relief treatment across these establishments and the increased adoption of minimally invasive procedures will propel patient footfalls across hospitals. Thus, creating a positive growth outlook for the joint pain injection industry.

Robust technological landscape to aid industry growth across North America

Global joint pain injections market by region

Get more details on this report - Request Free Sample PDF

North America joint pain injection market is expected to showcase over 7.5% CAGR between 2023 and 2032. The regional growth can be attributed to the growing prominence of arthritis & other orthopedic disorders among the elderly and the strong presence of major industry participants undertaking several R&D initiatives focused on enhancing product efficacy. The high procedural outcomes and clinical success rate driven by certain technological advancements will further open substantial growth avenues for the regional industry.

New product innovations to strengthen the competitive outlook

Major companies operating in the joint pain injections market include Zimmer Biomet, Anika Therapeutics, Inc., Bioventus, Sanofi, Pfizer, and others. Players in the market have been focusing on introducing novel joint pain treatments to ensure better pain relief and management in patients suffering from joint disorders.

Impact of COVID-19 on the joint pain injections market

The COVID-19 outbreak had a negative influence on the joint pain injection industry, especially in 2020. The surging incidences of COVID-19 infections and the increased mortality rate resulted in the delay and postponement of non-essential medical procedures. Besides, several governments, including the U.S, imposed a ban on all elective procedures in inpatient and outpatient settings, which further hampered the market growth. However, in 2021, the emergence of telemedicine facilities and the resumed healthcare services across several countries helped the industry revival. In addition, a significant rise in joint pain treatment therapies will stimulate the industry revenue streams through 2032.

Global joint pain injections market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2018 to 2032 for the following segments:

By Injection Type

  • Hyaluronic Acid Injections
  • Corticosteroid Injections
  • Platelet Rich Plasma Injections

By Joint Type 

  • Knee
  • Shoulder & Elbow
  • Ankle & Hip
  • Others

By End-use

  • Hospitals
  • Clinics
  • Others

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE


Authors: Sumant Ugalmugle, Rupali Swain

Frequently Asked Questions (FAQ) :

Global market size for joint pain injections stood at over USD 3.5 billion in 2022 and is anticipated to showcase more than 8.5% CAGR from 2023 to 2032 owing to a significant rise in the prevalence of musculoskeletal conditions and orthopedic disorders.

Joint pain injection industry size from the hospital segment is expected to amass over USD 5.4 billion by 2032 owing to the easy accessibility to advanced medical equipment and skilled orthopedic surgeons across these facilities.

North America joint pain injection market is projected to witness more than 7.5% CAGR between 2023 and 2032 driven by the consistent rise in the geriatric population and strong competitive landscape across the region.

Prominent enterprises operating in the global market include Zimmer Biomet, Anika Therapeutics, Inc., Bioventus, Sanofi, Pfizer, and others

Buy Now

Access to only 1 person; cannot be shared; cannot be printed
Access for 2 to 5 users only within same department of one company
Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Premium Report Details

  • Base Year: 2022
  • Companies covered: 13
  • Tables & Figures: 196
  • Countries covered: 18
  • Pages: 180

Get a report that explains COVID-19 impact on this market

 Request Free Sample

Budget constraints? Get in touch with us for special pricing

Request Discount